AllianceBernstein’s Trevi Therapeutics TRVI Stock Holding History

AllianceBernstein’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$35.6M	Sell	2,845,472 -237,514	-8%	-$2.66M	0.01%	704
2025 Q4	$38.6M	Sell	3,082,986 -1,209,465	-28%	-$14M	0.01%	708
2025 Q3	$39.3M	Buy	4,292,451 +11,096	+0.3%	+$83.2K	0.01%	684
2025 Q2	$23.4M	Buy	4,281,355 +4,259,015	+19,065%	+$26.5M	0.01%	845
2025 Q1	$141K	Buy	22,340 +6,900	+45%	+$32.9K	﹤0.01%	3011
2024 Q4	$63.6K	Hold	15,440	–	–	﹤0.01%	3170
2024 Q3	$51.6K	Hold	15,440	–	–	﹤0.01%	3188
2024 Q2	$46K	Buy	+15,440	New	+$42.9K	﹤0.01%	3197

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

AllianceBernstein's TRVI Position: Q1 2026 in Review

AllianceBernstein reduced its Trevi Therapeutics (TRVI) stake by 7.7% in Q1 2026, selling an estimated $2.66M and leaving 2,845,472 shares worth $35.6M. The position accounts for 0.01% of the portfolio, ranked #704.

AllianceBernstein first reported a position in TRVI in Q2 2024 and has held it in 8 quarters since. The position peaked at $39.3M in Q3 2025. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

AllianceBernstein held 2,845,472 shares of Trevi Therapeutics worth $35.6M as of Q1 2026.
AllianceBernstein sold 237,514 Trevi Therapeutics shares in Q1 2026, an estimated $2.66M.
Trevi Therapeutics made up 0.01% of AllianceBernstein's portfolio in Q1 2026, its #704 holding.
AllianceBernstein first reported a position in Trevi Therapeutics in Q2 2024 and has held it in 8 quarters since.
AllianceBernstein's Trevi Therapeutics position peaked at $39.3M in Q3 2025.
198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.